| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 49 companies in the Life Sciences Tools & Services industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jan 11, 2021 | GH Guardant Health, Inc. | Meresman Stanley J75 | Director | Sell | 4,934 | $142.00 | $700,628.00 | -54.9% | |
| Jan 11, 2021 | XGN Exagen Inc. | Hunt Holdings Limited Partnership | 10% Owner | Sell | 32,580 | $16.05 | $522,964.84 | -0.7% | |
| Jan 8, 2021 | MEDP Medpace Holdings, Inc. | Troendle August J.71 | President &CEO | Sell | 26,666 | $140.71 | $3,752,172.86 | -0.4% | |
| Jan 8, 2021 | NDRA Endra Life Sciences Inc. | Tokman Alexander Y | Director | Sell | 10,000 | $0.90 | $9,000.00 | -23.3% | |
| Jan 8, 2021 | MYGN Myriad Genetics Inc | Parkinson Paul | EVP Strategy And Innovation | Sell | 11,824 | $25.00 | $295,600.00 | -13.3% | |
| Jan 8, 2021 | MEDP Medpace Holdings, Inc. | Medpace Investors, LLC69 | 10% Owner | Sell | 26,666 | $140.71 | $3,752,172.86 | -0.4% | |
| Jan 8, 2021 | NDRA Endra Life Sciences Inc. | Maloberti Renaud Bertrand | Chief Commercial Officer | Sell | 8,731 | $0.94 | $8,207.14 | -28.8% | |
| Jan 7, 2021 | MEDP Medpace Holdings, Inc. | Troendle August J.71 | President &CEO | Sell | 185,219 | $140.06 | $25,941,773.14 | -1.4% | |
| Jan 7, 2021 | MEDP Medpace Holdings, Inc. | Medpace Investors, LLC69 | 10% Owner | Sell | 185,219 | $140.06 | $25,941,773.14 | -1.4% | |
| Jan 6, 2021 | NDRA Endra Life Sciences Inc. | Maloberti Renaud Bertrand | Chief Commercial Officer | Sell | 11,269 | $0.94 | $10,592.86 | -27.1% | |
| Jan 6, 2021 | RVTY Revvity, Inc. | Goldberg Joel S58 | Please See Remarks | Sell | 26,667 | $155.35 | $4,142,693.71 | -4.0% | |
| Jan 6, 2021 | NDRA Endra Life Sciences Inc. | Wells David R. | Chief Financial Officer | Sell | 35,000 | $0.90 | $31,500.00 | -15.2% | |
| Jan 5, 2021 | RVTY Revvity, Inc. | Singh Prahlad R.53 | Please See Remarks | Sell | 10,636 | $150.00 | $1,595,400.00 | -21.0% | |
| Jan 5, 2021 | CDNA Caredx, Inc. | Maag Peter83 | Executive Chair | Sell | 10,000 | $71.92 | $719,237.42 | -1.2% | |
| Jan 4, 2021 | MEDP Medpace Holdings, Inc. | Troendle August J.71 | President &CEO | Sell | 10,127 | $140.01 | $1,417,881.27 | -0.2% | |
| Jan 4, 2021 | GH Guardant Health, Inc. | Clark Ian T66 | Director | Sell | 2,690 | $129.23 | $347,628.70 | -36.7% | |
| Jan 4, 2021 | CRL Charles River Laboratories International, Inc. | Smith David Ross63 | Corporate Executive VP &CFO | Sell | 5,000 | $248.76 | $1,243,788.42 | -2.3% | |
| Jan 4, 2021 | VCYT Veracyte, Inc. | Gordon Kevin K51 | Director | Sell | 10,000 | $48.98 | $489,798.36 | -64.4% | |
| Jan 4, 2021 | MEDP Medpace Holdings, Inc. | Medpace Investors, LLC69 | 10% Owner | Sell | 10,127 | $140.01 | $1,417,881.27 | -0.2% | |
| Jan 4, 2021 | EXAS Exact Sciences Corp | Conroy Kevin T81 | President And CEO | Sell | 31,814 | $128.74 | $4,095,734.36 | -3.7% | |
| Dec 30, 2020 | MEDP Medpace Holdings, Inc. | Troendle August J.71 | President &CEO | Sell | 19,930 | $140.01 | $2,790,399.30 | -0.3% | |
| Dec 30, 2020 | MEDP Medpace Holdings, Inc. | Medpace Investors, LLC69 | 10% Owner | Sell | 19,930 | $140.01 | $2,790,399.30 | -0.3% | |
| Dec 30, 2020 | CSTL Castle Biosciences Inc | Maetzold Derek J69 | Pres. &Chief Exec. Officer | Sell | 30,000 | $67.52 | $2,025,743.22 | -0.2% | |
| Dec 29, 2020 | CSTL Castle Biosciences Inc | Bradbury Daniel69 | Director | Sell | 30,000 | $69.69 | $2,090,782.09 | -0.3% | |
| Dec 28, 2020 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 300,000 | $4.00 | $1,199,500.00 | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.